Bcl-2-like protein 1 (BCL2L1) (BCL2L1)

Bcl-2-like protein 1 (BCL2L1), primarily known for its anti-apoptotic isoform Bcl-xL, is a critical regulator of the intrinsic (mitochondrial) apoptotic pathway [1.2.2, 1.3.1]. As a member of the Bcl-2 family, it resides on the outer mitochondrial membrane and prevents cell death by sequestering pro-apoptotic proteins such as BAX, BAK, and BIM, thereby maintaining mitochondrial integrity [1.1.3, 1.2.3]. BCL2L1 is frequently overexpressed in a variety of cancers, including hematologic malignancies and solid tumors like colorectal and breast cancer, where it promotes survival and resistance to therapy [1.3.2, 1.4.1]. It also plays roles in non-apoptotic processes such as autophagy regulation and synaptic plasticity [1.1.3, 1.4.2]. Therapeutic strategies targeting BCL2L1 include BH3 mimetics, which competitively inhibit its anti-apoptotic function to induce tumor cell death [1.3.4, 1.4.4]. However, the clinical utility of BCL2L1 inhibitors is often limited by dose-dependent thrombocytopenia, as Bcl-xL is essential for the survival of mature platelets [1.2.1].

Other names

Bcl-xLBcl-xBcl-xSBCLXBCL2LPPP1R52Apoptosis regulator Bcl-XBcl2-L-1

BH3 mimetic; binds to the hydrophobic BH3-binding groove of anti-apoptotic Bcl-2 family proteins (primarily Bcl-xL), displacing pro-apoptotic proteins (e.g., BIM, BAX, BAK) to trigger mitochondrial outer membrane permeabilization (MOMP) and subsequent apoptosis [1.3.4, 1.4.3].